TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01294410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
Study: NCT03290222

Intervention type: OTHER
Intervention: TRACK questionnaire
Description: TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
Study: NCT02468310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal emergency protocols
Description: Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
Study: NCT00868764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
Study: NCT01767662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manipulation
Description: home programme

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: observation
Study: NCT01404533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 60 mg Ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 60 mg ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 6 mg ferrous sulfate
Study: NCT02849821

Intervention type: OTHER
Group type: OTHER
Intervention: hypobaric pressure chamber
Description: hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control

Intervention type: OTHER
Group type: OTHER
Intervention: Sigmoidoscopy
Description: To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
Study: NCT03354247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
Study: NCT03246230

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine (HBV)
Description: Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine (HBV)
Description: Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
Study: NCT04183244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block
Description: A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular subomohyoid (ISO) block
Description: Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
Study: NCT02350855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Atta
Description: Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
Study: NCT04655742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow™ Transcatheter Aortic Valve System
Description: VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
Study: NCT03188536

Intervention type: OTHER
Intervention: No Intervention
Description: As it was an observational study, no intervention was administered in this study.
Study: NCT02146729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pedicle Screw Fixation
Description: Percutaneous Pedicle Screw Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Treatment
Description: Midline posterior incision with instrumentation.
Study: NCT04052997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab Tesirine
Description: Intravenous Infusion
Study: NCT00193596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg alternating with 100 mg PO, days 1 and 10 in regimen A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV, days 1 and 8, in regimen B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 1000 mg/m2 IV days 1 and 8 in regimen B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 by 1-hour IV infusion, day 1, regimen A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) 6.0 IV, day 1, regimen A
Study: NCT03935061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
Study: NCT03100136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PF-06809247
Description: PET Tracer
Study: NCT03292497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment Algorithm
Description: Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Treatment Algorithm
Description: Patients will have their valve repaired or replaced at the discretion of their surgeon.
Study: NCT02710097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled cannabis
Description: \~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.
Study: NCT03246230

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
Study: NCT02710097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled cannabis
Description: \~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.
Study: NCT00723918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAB378
Description: SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAB placebo
Description: an inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAB placebo
Description: an inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone placebo
Description: Methadone placebo
Study: NCT02024750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Resources
Description: Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
Study: NCT01100918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiV ICD
Description: Biventricular ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiV ICD
Description: Biventricular ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD
Description: Implantable Defibrillator
Study: NCT02301364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120)
Description: Buparlisib 100 mg once daily.
Study: NCT01497340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position at introitus level
Description: After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position at Maternal Abdomen
Description: Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
Study: NCT00887185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulator training for temporal bone surgery
Description: Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
Study: NCT04579926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinpoint app
Description: Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
Study: NCT02588573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (control)
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (control)
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A (test)
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A (test)
Description: contact lens
Study: NCT01341639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INFANRIX™ hexa
Description: INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Description: RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
Study: NCT00887185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training for temporal bone surgery
Description: Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
Study: NCT01748123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
Study: NCT01643798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
Study: NCT03772613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Administration of unfractionated heparin will be assessed using the activated clotting time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Administration of unfractionated heparin will be assessed using the activated clotting time
Study: NCT01643798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS
Description: An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
Study: NCT03772613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Administration of unfractionated heparin will be assessed using the activated clotting time
Study: NCT01643798

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Real rTMS
Description: An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
Study: NCT02360202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impedance analysis
Description: Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate cream treatment
Description: clobetasol propionate treatment initiated following French recommendations
Study: NCT02666638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Volunteers
Description: MRI on up to a 7T scanner without contrast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Volunteers
Description: One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
Study: NCT01053520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
Study: NCT04092829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE
Description: The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
Study: NCT03597022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befovacimab (BAY1093884)
Description: Once weekly doses until premature termination of the study, subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befovacimab (BAY1093884)
Description: Once weekly doses until premature termination of the study, subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befovacimab (BAY1093884)
Description: Once weekly doses until premature termination of the study, subcutaneous injection
Study: NCT00223730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03061240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart pain assessment tool
Description: We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
Study: NCT01635907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib